Sistemic hires more staff
Moves to larger premises that will become new global hq
The company says this will enable it to fulfil current contracts more rapidly, while providing further capacity for newly acquired and future contracts. It will also support the expansion of its key internal r&d programmes in drug toxicology and stem cell characterisation.
The expansion programme will also see the company grow its US commercial operations by developing its Boston location and opening an office in California.
David Mallinson, who previously worked for Merck Sharpe Dohme (MSD), has joined Sistemic as a senior scientist and will lead new projects at the expanded facility.
Max Bylesjo, previously at Almac Group, has joined as senior bioinformatician and will focus on developing Sistemic’s data processing technology.
The new Sistemic headquarters will dedicate 60% of its space to laboratory facilities, equipped with state-of-the-art technology, and 40% as new commercial areas.
You may also like
Research & Development
Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research
Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development
AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic
The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies